The purpose of this study is to describe the course of COVID-19 infection in patients with chronic lymphocytic leukemia (CLL). Patients with CLL are an estimated risk group of patients for severe course of COVID-19 infection. The main goal is to clarify the mortality 28 days from the time of proven COVID-19 infection in patients with CLL.
The sub-goals are three:
1. Describe baseline characteristics, past and current treatment for CLL, clinical course of COVID-19 infection for patients with CLL.
2. Investigate the possible relationship between the treatment of patients' CLL and the clinical course of COVID-19 infection.
3. Clarify the current practice of implementing CLL-targeted therapy in patients with COVID-19 infection